表纸
市场调查报告书

中风:流行病学、患者为基础的市场预测,治疗流程,及上市药、开发平台药物分析

Ischemic Stroke Market and Forecast Analysis 2024

出版商 Datamonitor Healthcare 商品编码 365165
出版日期 内容资讯 英文 163 Pages
商品交期: 最快1-2个工作天内
价格
中风:流行病学、患者为基础的市场预测,治疗流程,及上市药、开发平台药物分析 Ischemic Stroke Market and Forecast Analysis 2024
出版日期: 2019年01月07日内容资讯: 英文 163 Pages
简介

带来本报告以缺血性中风的治疗药为焦点,提供作为Xarelto的解毒剂的andexanet alfa的认证带给药物销售额的影响,带给缺血性中风治疗药销售额最大影响的患者亚组,影响医生处方趋势的最重要要素,缺血性中风的治疗上构成最大市场占有率的首发药,缺血性中风的急性治疗、二次预防双方最常见的治疗药等相关分析。

预测:缺血性中风

  • 摘要整理
  • 市场概要、趋势
  • 市场定义、调查手法
  • Brilinta (ticagrelor)
  • Plavix (clopidogrel)
  • Xarelto (rivaroxaban)
  • 1次调查手法

治疗:缺血性中风

  • 摘要整理
  • 1次调查手法
  • 疾病定义、诊断
  • 目前治疗选择
  • 处方趋势

流行病学:中风

  • 摘要整理
  • 疾病的背景
  • 来源、手法
  • 预测
  • 流行病学者的考察
  • 能力与限制

上市药:缺血性中风

  • 摘要整理
  • 产品概要
  • 产品简介:Activase
  • 产品简介:Aggrenox
  • 产品简介:Plavix

开发平台:缺血性中风

  • 摘要整理
  • 临床实验平台概要
  • 最近中止的药物
  • 产品简介 (后期阶段) :Ampyra
  • 产品简介 (后期阶段) :Brilinta
  • 产品简介 (后期阶段) :Xarelto
目录
Product Code: DMKC12560

Overview

Stroke is the second most common cause of death and a major cause of disability worldwide. A stroke occurs when there is a blockage or bleed in the cerebrovascular system that leads to either a neurological deficit persisting beyond 24 hours or death. The majority of strokes occur due to blockages, and these are known as ischemic strokes. Strokes caused by bleeding are known as hemorrhagic strokes.

Market Snapshot

  • Market growth will slow as Plavix continues to lose market share as generic clopidogrel uptake increases.
  • Alteplase is prescribed to 65% of ischemic stroke patients in the US, Japan, and five major EU markets who receive thrombolytic therapy as an acute treatment.
  • Overall disease burden is expected to greatly increase, with ischemic stroke more common than hemorrhagic stroke.
  • Activase will continue to experience strong uptake while Aggrenox and Plavix face declining sales.
  • The large-scale Xarelto study was recently suspended, and there are no other pipeline drugs in Phase III trials.

TABLE OF CONTENTS

FORECAST: ISCHEMIC STROKE (Published on 02 July 2018)

  • OVERVIEW
  • MARKET OVERVIEW AND TRENDS
  • MARKET DEFINITION AND METHODOLOGY
  • PRIMARY RESEARCH METHODOLOGY
  • BIBLIOGRAPHY
  • PRODUCT PROFILE: ASPIRIN
  • PRODUCT PROFILE: PLAVIX

TREATMENT: ISCHEMIC STROKE (Published on 14 December 2016)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRIMARY RESEARCH METHODOLOGY
  • DISEASE DEFINITION AND DIAGNOSIS
  • CURRENT TREATMENT OPTIONS
  • PRESCRIBING TRENDS

EPIDEMIOLOGY: STROKE (Published on 07 January 2019)

  • OVERVIEW
  • DISEASE BACKGROUND
  • METHODOLOGY
  • FORECAST
  • BIBLIOGRAPHY
  • APPENDIX: ADDITIONAL SOURCES

MARKETED DRUGS: ISCHEMIC STROKE (Published on 02 July 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • PRODUCT OVERVIEW
  • PRODUCT PROFILE: ACTIVASE
  • PRODUCT PROFILE: AGGRENOX
  • PRODUCT PROFILE: ASPIRIN
  • PRODUCT PROFILE: PLAVIX

PIPELINE: ISCHEMIC STROKE (Published on 02 July 2018)

  • OVERVIEW
  • EXECUTIVE SUMMARY
  • CLINICAL PIPELINE OVERVIEW
  • RECENTLY DISCONTINUED DRUGS
  • ADDITIONAL PHARMA INTELLIGENCE PIPELINE RESOURCES

LIST OF FIGURES

  • Figure 1: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 2: Ischemic stroke market forecast across the US, Japan, and five major EU markets, by drug, 2016-25
  • Figure 3: Patient-based forecast methodology for ischemic stroke
  • Figure 4: Price sources and calculations, by country
  • Figure 5: Datamonitor Healthcare's drug assessment summary of Aspirin for ischemic stroke
  • Figure 6: Datamonitor Healthcare's drug assessment summary of Aspirin for ischemic stroke
  • Figure 7: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 8: Plavix for ischemic stroke - SWOT analysis
  • Figure 9: Datamonitor Healthcare's drug assessment summary of Plavix for ischemic stroke
  • Figure 10: Datamonitor Healthcare's drug assessment summary of Plavix for ischemic stroke
  • Figure 11: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 12: Mean percentage of patients presenting with stroke-like symptoms diagnosed with particular indications, by country, 2015
  • Figure 13: Mean percentage of ischemic stroke patients receiving each treatment regimen in the US, Japan, and five major EU markets, by country, 2015
  • Figure 14: Mean percentage of ischemic stroke patients receiving each thrombolytic therapy in the US, Japan, and five majorEU markets, by country, 2015
  • Figure 15: Mean percentage of ischemic stroke patients receiving each neuroprotective therapy in the US, Japan, and five major EU markets, by country, 2015
  • Figure 16: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the acute treatment setting, by country, 2015
  • Figure 17: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in the secondary prevention setting at first-line, by country, 2015
  • Figure 18: Mean percentage of ischemic stroke patients who progress to second-line treatment in the secondary prevention setting, by country, 2015
  • Figure 19: Ischemic stroke patients receiving the top five antiplatelet/anticoagulant medications in secondary prevention setting at second-line, by country, 2015
  • Figure 20: Trends in diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 21: Trends in diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 22: Trend in diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 23: Trends in diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Figure 24: Activase for ischemic stroke - SWOT analysis
  • Figure 25: Datamonitor Healthcare's drug assessment summary of Activase for ischemic stroke
  • Figure 26: Datamonitor Healthcare's drug assessment summary of Activase for ischemic stroke
  • Figure 27: Aggrenox for ischemic stroke - SWOT analysis
  • Figure 28: Datamonitor Healthcare's drug assessment summary of Aggrenox for ischemic stroke
  • Figure 29: Datamonitor Healthcare's drug assessment summary of Aggrenox for ischemic stroke
  • Figure 30: Datamonitor Healthcare's drug assessment summary of Aspirin for ischemic stroke
  • Figure 31: Datamonitor Healthcare's drug assessment summary of Aspirin for ischemic stroke
  • Figure 32: Aspirin sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016-25
  • Figure 33: Plavix for ischemic stroke - SWOT analysis
  • Figure 34: Datamonitor Healthcare's drug assessment summary of Plavix for ischemic stroke
  • Figure 35: Datamonitor Healthcare's drug assessment summary of Plavix for ischemic stroke
  • Figure 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country, 2016-25

LIST OF TABLES

  • Table 1: Distribution of total market sales across ischemic stroke subgroups, 2016-25
  • Table 2: Summary of drug classes and molecules included in Datamonitor Healthcare's ischemic stroke patient-based forecast
  • Table 3: Patent expiries occurring within the ischemic stroke market during the forecast period, 2016-25
  • Table 4: Exchange rates used for calculating prices
  • Table 5: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
  • Table 6: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 7: Plavix drug profile
  • Table 8: Plavix pivotal trial data in ischemic stroke
  • Table 9: Plavix ongoing late-phase clinical trials in ischemic stroke
  • Table 10: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 11: Cardiologists and neurologists surveyed for the ischemic stroke primary research study, 2015
  • Table 12: Overview of risk factors for a first transient ischemic attack or ischemic stroke
  • Table 13: Mean percentage of ischemic stroke patients that have co-morbidities in the US, Japan, and five major EU markets, by country, 2015
  • Table 14: Common transient ischemic attack and ischemic stroke symptoms
  • Table 15: Overview of tests used in ischemic stroke and transient ischemic attack patients, by major category
  • Table 16: Treatments available for ischemic stroke across the US, Japan, and five major EU markets
  • Table 17: Mean percentage of ischemic stroke patients receiving each type of therapy in the US, Japan, and five major EU markets, by country, 2015
  • Table 18: Overview of inclusion and exclusion criteria for patients eligible for alteplase treatment in the US
  • Table 19: Mean percentage of ischemic stroke patients that progress to secondary prevention in the US, Japan, and five major EU markets, by country, 2015
  • Table 20: Sources used for the epidemiological analysis of stroke incidence in the US, Japan, and five major EU markets, by country
  • Table 21: Sources used for the epidemiological analysis of stroke prevalence in the US, Japan, and five major EU markets, by country
  • Table 22: Diagnosed incident cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 23: Diagnosed incident cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 24: Diagnosed prevalent cases of ischemic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 25: Diagnosed prevalent cases of hemorrhagic stroke in the US, Japan, and five major EU markets, by country, 2018-38
  • Table 26: Key marketed drugs for ischemic stroke
  • Table 27: Activase drug profile
  • Table 28: Activase pivotal trial data in ischemic stroke
  • Table 29: Aggrenox drug profile
  • Table 30: Aggrenox pivotal trial data in ischemic stroke
  • Table 31: Aggrenox late-phase trial data in ischemic stroke
  • Table 32: Aspirin franchise sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 33: Plavix drug profile
  • Table 34: Plavix pivotal trial data in ischemic stroke
  • Table 35: Plavix ongoing late-phase clinical trials in ischemic stroke
  • Table 36: Plavix sales for ischemic stroke across the US, Japan, and five major EU markets, by country ($m), 2016-25
  • Table 37: Late-stage compounds that were recently discontinued for ischemic stroke
  • Table 38: Ampyra drug profile
  • Table 39: Ampyra late-phase trial data in ischemic stroke
  • Table 40: Brilinta drug profile
  • Table 41: Brilinta late-phase trial data in ischemic stroke
  • Table 42: Desmoteplase drug profile
  • Table 43: Desmoteplase late-phase trial data in ischemic stroke
  • Table 44: Xarelto drug profile
  • Table 45: Xarelto late-phase trial data in ischemic stroke